Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gout sufferers could soon track uric acid with a simple skin patch

NCT ID NCT06187519

Knowledge-focused Sponsor: University of California, Los Angeles Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new skin patch system called UR+AIMS that measures uric acid levels in people with gout. Six participants wore the patch for a week and during a standard meal to see if it was comfortable and gave accurate readings. The goal is to help patients better understand how their diet and medications affect their uric acid levels.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Uric Acid and Metabolite Monitor System (UR+AIMS) skin patch
What this could lead to
If it works, this could lead to a simple skin patch that helps people with gout track their uric acid levels in real time, making it easier to manage their condition through diet and medication.
What could go wrong
This is a very small, early-stage lab validation study with only 6 participants, so results may not apply to everyone. The patch might be uncomfortable or inaccurate, and it's not yet proven to improve health outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

6 people

The number who actually took part.

Started

Mar 2025

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age \> 18 with diagnosis of gout (screening positive ACR/EULAR Gout Classification Criteria - see screening survey) and eGFR \> 60 (within the last 12-months). 2. For the 10 patients with gout off urate-lowering therapy (ULT) \[no Allopurinol, febuxostat, or probenecid prescription within the last 6-months\] and serum urate (SU) \> 7 mg/dL (within the last 12-months). 3. For the 5 patients with gout on urate-lowering therapy (ULT) \[no dose change within the last 30 days\]. Exclusion Criteria: 1. Contraindications to miosis, which include acute iritis, narrow-angle glaucoma 2. Known Hypersensitivity to pilocarpine hydrochloride 3. Pupillary block glaucoma (ophthalmic solution) 4. Subjects reporting any allergy to glue or latex or any allergy to food that will be provided in the study (sardines in extra virgin olive oil and Sprite).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gout are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gout

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gout

Contacts and locations

Locations

  • UCLA

    Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.